INTRODUCTION The aim of this study is to determine whether 99mTc-MAA SPECT/CT-based dosimetry could predict the actual absorbed dose in hepatocellular carcinoma (HCC) or liver metastases, treated by glass or resin microspheres. MATERIAL AND METHODS Fifty-seven patients who underwent selective internal radiation therapy (SIRT) were retrospectively included in the study, for a total of 59 treatments. Nineteen HCC were treated by resin microspheres (HCC-SIR), 20 HCC with glass microspheres (HCC-Thera), and 20 liver metastases with resin microspheres (Metastases-SIR). The mean absorbed doses in tumoral liver (Dm) and non-tumoral liver (DmNTL) were determined on the 99mTc-MAA SPECT/CT and the 90Y PET/CT, and compared with each other. RESULTS DmNTL was < 50 Gy in the 3 groups, with a strong correlation in all population, albeit slightly lower in Metastases-SIR than HCC-SIR and HCC-Thera (CCC 0.8, 0.94 and 0.96, respectively). In tumoral liver, Dm was higher in HCC than metastases (159 ± 117 Gy versus 63 ± 31 Gy). 99mTc-MAA SPECT/CT proved to be a better indicator of Dm in HCC compared with metastases, with similar 99mTc-MAA-90Y concordance in resin and glass microspheres (CCC HCC-SIR 0.82, CCC HCC-Thera 0.82, and CCC Metastases-SIR 0.52). CONCLUSION 99mTc-MAA SPECT/CT is a reasonably reliable tool for predicting the dose to the non-tumoral liver in both HCC and metastases, regardless of the type of microspheres. It is also fairly reliable for predicting the tumor dose in HCC, again regardless of the type of spheres, although individual variations are observed.

中文翻译：

---

原发性和转移性肝肿瘤中99mTc-MAA SPECT / CT和90Y PET / CT之间的比较剂量测定。

引言这项研究的目的是确定基于99mTc-MAA SPECT / CT的剂量测定法能否预测玻璃或树脂微球治疗的肝细胞癌（HCC）或肝转移的实际吸收剂量。材料与方法回顾性分析了57例接受了选择性内部放射治疗（SIRT）的患者，共进行59种治疗。树脂微球（HCC-SIR）治疗19例肝癌，玻璃微球（HCC-Thera）治疗20例肝癌，树脂微球（Metastases-SIR）治疗20例肝转移。在99mTc-MAA SPECT / CT和90Y PET / CT上确定肿瘤肝（Dm）和非肿瘤肝（DmNTL）的平均吸收剂量，并将它们相互比较。结果3组的DmNTL <50 Gy，在所有人群中都有很强的相关性，尽管Metastases-SIR中的水平略低于HCC-SIR和HCC-Thera（CCC分别为0.8、0.94和0.96）。在肿瘤肝中，肝癌中的Dm高于转移灶（159±117 Gy对63±31 Gy）。与转移相比，99mTc-MAA SPECT / CT被证明是更好的HCC Dm指标，在树脂和玻璃微球体中具有相似的99mTc-MAA-90Y一致性（CCC HCC-SIR 0.82，CCC HCC-Thera 0.82和CCC Metastases- SIR 0.52）。结论99mTc-MAA SPECT / CT是预测HCC和转移中非肿瘤肝剂量的合理可靠工具，而与微球类型无关。同样，无论球的类型如何，尽管可以观察到个体差异，但预测HCC中的肿瘤剂量也相当可靠。在肝癌中，Dm高于转移灶（159±117 Gy与63±31 Gy）。与转移相比，99mTc-MAA SPECT / CT被证明是更好的HCC Dm指标，在树脂和玻璃微球体中具有相似的99mTc-MAA-90Y一致性（CCC HCC-SIR 0.82，CCC HCC-Thera 0.82和CCC Metastases- SIR 0.52）。结论99mTc-MAA SPECT / CT是预测HCC和转移中非肿瘤肝剂量的合理可靠工具，而与微球类型无关。同样，无论球的类型如何，尽管可以观察到个体差异，但预测HCC中的肿瘤剂量也相当可靠。在肝癌中，Dm高于转移灶（159±117 Gy与63±31 Gy）。与转移相比，99mTc-MAA SPECT / CT被证明是更好的HCC Dm指标，在树脂和玻璃微球体中具有相似的99mTc-MAA-90Y一致性（CCC HCC-SIR 0.82，CCC HCC-Thera 0.82和CCC Metastases- SIR 0.52）。结论99mTc-MAA SPECT / CT是预测HCC和转移中非肿瘤肝剂量的合理可靠工具，而与微球类型无关。同样，无论球的类型如何，尽管可以观察到个体差异，但预测HCC中的肿瘤剂量也相当可靠。在树脂和玻璃微球中具有相似的99mTc-MAA-90Y一致性（CCC HCC-SIR 0.82，CCC HCC-Thera 0.82和CCC Metastases-SIR 0.52）。结论99mTc-MAA SPECT / CT是预测HCC和转移中非肿瘤肝剂量的合理可靠工具，而与微球类型无关。同样，无论球的类型如何，尽管可以观察到个体差异，但预测HCC中的肿瘤剂量也相当可靠。在树脂和玻璃微球中具有相似的99mTc-MAA-90Y一致性（CCC HCC-SIR 0.82，CCC HCC-Thera 0.82和CCC Metastases-SIR 0.52）。结论99mTc-MAA SPECT / CT是预测肝癌和转移中非肿瘤性肝癌剂量的合理可靠工具，而与微球类型无关。同样，无论球的类型如何，尽管可以观察到个体差异，但预测HCC中的肿瘤剂量也相当可靠。